{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:20:38Z","timestamp":1778707238135,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,8]],"date-time":"2013-06-08T00:00:00Z","timestamp":1370649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00059-013-3816-0","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T16:35:49Z","timestamp":1370536549000},"page":"868-880","source":"Crossref","is-referenced-by-count":31,"title":["Cabergoline use and risk of fibrosis and insufficiency of cardiac valves","Cabergolingabe und Risiko einer Fibrose mit Herzklappeninsuffizienz"],"prefix":"10.1007","volume":"38","author":[{"given":"R.","family":"De Vecchis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ariano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,8]]},"reference":[{"key":"3816_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346","journal-title":"N Engl J Med"},{"key":"3816_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338","journal-title":"N Engl J Med"},{"key":"3816_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"Roth","year":"2007","unstructured":"Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6\u20139","journal-title":"N Engl J Med"},{"key":"3816_CR4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","volume":"95","author":"Valassi","year":"2010","unstructured":"Valassi E, Klibanski A, Biller BM (2010) Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95(3):1025\u20131033","journal-title":"J Clin Endocrinol Metab"},{"key":"3816_CR5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","volume":"348","author":"Moller","year":"2003","unstructured":"Moller JE, Connolly HM, Rubin J et al (2003) Factors associated with progression of carcinoid heart disease. N Engl J Med 348:1005\u20131015","journal-title":"N Engl J Med"},{"key":"3816_CR6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","volume":"90","author":"Fox","year":"2004","unstructured":"Fox DJ, Khattar RS (2004) Carcinoid heart disease: presentation, diagnosis, and management. Heart 90:1224\u20131228","journal-title":"Heart"},{"key":"3816_CR7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","volume":"159","author":"Kars","year":"2008","unstructured":"Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159(4):363\u2013367 (Epub 14 Aug 2008)","journal-title":"Eur J Endocrinol"},{"key":"3816_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-011-0339-7","volume":"15","author":"Boguszewski","year":"2012","unstructured":"Boguszewski CL, Santos CM dos, Sakamoto KS et al (2012) A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary 15(1):44\u201349","journal-title":"Pituitary"},{"key":"3816_CR9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","volume":"64","author":"Corvol","year":"2007","unstructured":"Corvol JC, Anzouan-Kacou JB, Fauveau E et al (2007) Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 64:1721\u20131726","journal-title":"Arch Neurol"},{"key":"3816_CR10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/mds.21639","volume":"22","author":"Simonis","year":"2007","unstructured":"Simonis G, Fuhrmann JT, Strasser RH (2007) Meta-analysis of heart valve abnormalities in Parkinson\u2019s disease patients treated with dopamine agonists. Mov Disord 22(13):1936\u20131942","journal-title":"Mov Disord"},{"key":"3816_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mds.23470","volume":"26","author":"Rasmussen","year":"2011","unstructured":"Rasmussen VG, \u00d8stergaard K, Dupont E, Poulsen SH (2011) The risk of valvular regurgitation in patients with Parkinson\u2019s disease treated with dopamine receptor agonists. Mov Disord 26(5):801\u2013806","journal-title":"Mov Disord"},{"key":"3816_CR12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/BF03345662","volume":"31","author":"Bogazzi","year":"2008","unstructured":"Bogazzi F, Manetti L, Raffaelli V et al (2008) Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31(12):1119\u20131123","journal-title":"J Endocrinol Invest"},{"key":"3816_CR13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200320110-00006","volume":"20","author":"Inzelberg","year":"2003","unstructured":"Inzelberg R, Schechtman E, Nisipeanu P (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson\u2019s disease: an evidence-based comparison. Drugs Aging 20(11):847\u2013855","journal-title":"Drugs Aging"},{"key":"3816_CR14","unstructured":"D\u2019Avella R, Comanducci T, Roghi A et al (2011) Morbo di Parkinson: dall\u2019analisi farmaco- epidemiologica alla definizione di un percorso per la gestione del paziente cronico (abstract; italian) in: ISTISAN: XX Seminario nazionale su -La valutazione dell\u2019uso e della sicurezza dei farmaci: esperienze in Italia\u2016, Italian National Health Institute, Rome"},{"key":"3816_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"Dos","year":"2011","unstructured":"Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259\u2013265","journal-title":"Pituitary"},{"key":"3816_CR16","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1210\/jc.85.9.3053","volume":"85","author":"Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC et al (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053\u20133057","journal-title":"J Clin Endocrinol Metab"},{"key":"3816_CR17","unstructured":"Food and Drug Administration (2007) Withdrawal of Parkinson\u2019s treatment: pergolide. http:\/\/www.fda.gov\/ForConsumers\/Consumer Updates\/ucm048819.htm. Accessed 15 Feb 2011"},{"key":"3816_CR18","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"3816_CR19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2007.01.011","volume":"109","author":"Kenangil","year":"2007","unstructured":"Kenangil G, Ozekmekci S, Koldas L et al (2007) Assessment of valvulopathy in Parkinson\u2019s disease patients on pergolide and\/or cabergoline. Clin Neurol Neurosurg 109:350\u2013353","journal-title":"Clin Neurol Neurosurg"},{"key":"3816_CR20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2796.2007.01874.x","volume":"263","author":"Rasmussen","year":"2008","unstructured":"Rasmussen VG, Poulsen SH, Dupont E et al (2008) Heart valve desease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson\u2019s disease. J Intern Med 263:90\u201398","journal-title":"J Intern Med"},{"key":"3816_CR21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","volume":"23","author":"Yamashiro","year":"2008","unstructured":"Yamashiro K, Komine-Kobayashi M, Hatano T et al (2008) The frequency of cardiac valvular regurgitation in Parkinson\u2019s disease. Mov Disord 23(7):935\u2013941","journal-title":"Mov Disord"},{"key":"3816_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","volume":"12","author":"Vallette","year":"2009","unstructured":"Vallette S, Serri K, Rivera J et al (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12(3):153\u2013157","journal-title":"Pituitary"},{"key":"3816_CR23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","volume":"21","author":"Peralta","year":"2006","unstructured":"Peralta C, Wolf E, Alber H et al (2006) Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study. Mov Disord 21(8):1109\u20131113","journal-title":"Mov Disord"},{"key":"3816_CR24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","author":"Yamamoto","year":"2006","unstructured":"Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67(7):1225\u20131229","journal-title":"Neurology"},{"key":"3816_CR25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","volume":"22","author":"Junghanns","year":"2007","unstructured":"Junghanns S, Fuhrmann JT, Simonis G et al (2007) Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234\u2013238","journal-title":"Mov Disord"},{"key":"3816_CR26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","volume":"35","author":"Trifir\u00f2","year":"2012","unstructured":"Trifir\u00f2 G, Mokhles MM, Dieleman JP et al (2012) Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson\u2019s disease and hyperprolactinaemia: a multi-country, nested case-control Study. Drug Saf 35(2):159\u2013171","journal-title":"Drug Saf"},{"key":"3816_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","volume":"159","author":"Lancellotti","year":"2008","unstructured":"Lancellotti P, Livadariu E, Markov M et al (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"3816_CR28","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","volume":"62","author":"Bogazzi","year":"2008","unstructured":"Bogazzi F, Buralli S, Manetti L et al (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62(12):1864\u20131869","journal-title":"Int J Clin Pract"},{"key":"3816_CR29","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER et al (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93(9):3348\u20133356","journal-title":"J Clin Endocrinol Metab"},{"key":"3816_CR30","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"Wakil","year":"2008","unstructured":"Wakil A, Rigby AS, Clark AL et al (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159(4):R11\u2013R14","journal-title":"Eur J Endocrinol"},{"key":"3816_CR31","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","volume":"93","author":"Colao","year":"2008","unstructured":"Colao A, Galderisi M, Di Sarno A et al (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93(10):3777\u20133784","journal-title":"J Clin Endocrinol Metab"},{"key":"3816_CR32","first-page":"104","volume":"Endocrinol","author":"Herring","year":"2009","unstructured":"Herring N, Szmigielski C, Becher H et al (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70(1):104\u2013108","journal-title":"Clin"},{"key":"3816_CR33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"Arranz","year":"2007","unstructured":"Arranz MJ, Leon J de (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707\u2013747","journal-title":"Mol Psychiatry"},{"key":"3816_CR34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/09540260701563460","volume":"19","author":"Malhotra","year":"2007","unstructured":"Malhotra AK, Lencz T, Correll CU, Kane JM (2007) Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 19:523\u2013530","journal-title":"Int Rev Psychiatry"},{"key":"3816_CR35","first-page":"797","volume":"19","author":"Izgi","year":"2010","unstructured":"Izgi C, Feray H, Cevik C et al (2010) Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis 19(6):797\u2013800","journal-title":"J Heart Valve Dis"},{"key":"3816_CR36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2230-8210.81949","volume":"15","author":"Bhat","year":"2011","unstructured":"Bhat MH, Mushtaq S, Saba S et al (2011) Cabergoline-induced tricuspid regurgitation: case report and review of literature. Indian J Endocrinol Metab 15(2):137\u2013139","journal-title":"Indian J Endocrinol Metab"},{"key":"3816_CR37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/pgmj.2009.090886","volume":"86","author":"Irwin","year":"2010","unstructured":"Irwin RB, Luckie M, Khattar RS (2010) Tricuspid regurgitation: contemporary management of a neglected valvular lesion. Postgrad Med J 86(1021):648\u2013655","journal-title":"Postgrad Med J"},{"key":"3816_CR38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/AC.67.2.2154218","volume":"67","author":"Moerman","year":"2012","unstructured":"Moerman VM, Dewilde D, Hermans K (2012) Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance. Acta Cardiol 67(2):245\u2013248","journal-title":"Acta Cardiol"},{"key":"3816_CR39","doi-asserted-by":"crossref","unstructured":"Maisch B, Christ M (2004) Extracardiac causes of right ventricular insufficiency. Internist (Berl) 45(10):1136\u20131146 (Article in German)","DOI":"10.1007\/s00108-004-1280-x"},{"key":"3816_CR40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0025-6196(11)62328-8","volume":"77","author":"Simula","year":"2002","unstructured":"Simula DV, Edwards WD, Tazelaar HD et al (2002) Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 77(2):139\u2013147","journal-title":"Mayo Clin Proc"},{"key":"3816_CR41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11886-012-0245-2","volume":"14","author":"Thapa","year":"2012","unstructured":"Thapa R, Dawn B, Nath J (2012) Tricuspid regurgitation: pathophysiology and management. Curr Cardiol Rep 14(2):190\u2013199","journal-title":"Curr Cardiol Rep"},{"key":"3816_CR42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E et al (2003) American society of echocardiography. recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16(7):777\u2013802","journal-title":"J Am Soc Echocardiogr"},{"key":"3816_CR43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"Van","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyns B et al (2004) Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179\u20131183","journal-title":"Lancet"},{"key":"3816_CR44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/mds.20931","volume":"21","author":"Kim","year":"2006","unstructured":"Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson\u2019s disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261\u20131264","journal-title":"Mov Disord"},{"key":"3816_CR45","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"Kvernmo","year":"2006","unstructured":"Kvernmo T, Hartter S, Burger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065\u20131078","journal-title":"Clin Ther"},{"key":"3816_CR46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","volume":"513","author":"Jahnichen","year":"2005","unstructured":"Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225\u2013228","journal-title":"Eur J Pharmacol"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-013-3816-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3816-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T22:48:17Z","timestamp":1715467697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-013-3816-0"}},"subtitle":["Meta-analysis of observational studies","Metaanalyse von Beobachtungsstudien"],"short-title":[],"issued":{"date-parts":[[2013,6,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3816"],"URL":"https:\/\/doi.org\/10.1007\/s00059-013-3816-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,8]]}}}